Phase i trial of sunitinib malate plus interferon-α for patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Fatigue
  • Kidney Neoplasms
  • Neutropenia
  • Thrombocytopenia

abstract

  • Although reduced starting doses were tolerated (37.5 mg for sunitinib and 3 MU for IFN-alpha), even these lower doses might not be well tolerated for long-term treatment of patients with metastatic RCC. Based on historical data, sunitinib on schedule 4/2 appears to be more effective as single-agent therapy. Further study of sunitinib plus IFN-alpha on this schedule is not being pursued in RCC.

publication date

  • September 28, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3394091

Digital Object Identifier (DOI)

  • 10.3816/CGC.2009.n.005

PubMed ID

  • 19213665

Additional Document Info

start page

  • 28

end page

  • 33

volume

  • 7

number

  • 1